Early histological transformation of follicular lymphoma to diffuse large B‐cell lymphoma indicating adverse survival: A population‐based analysis and validation
Cancer · 2024-10 · 130 (19) · 3321-3332
DOI: 10.1002/cncr.35378 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer, online erschienen am 29.05.2024. Verfasst von Zi-Hua Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Introduction
The histological transformation (HT) of follicular lymphoma (FL) is a crucial biological event. The study aimed to evaluate the incidence, clinicial characteristics, prognosis and impact of HT time on survival of FL transforming to diffuse large B‐cell lymphoma in population‐based large‐scale cohorts.
Methods
A retrospective cohort study of FL with HT was performed in the Surveillance, Epidemiology, and End Results database. The Hematological Malignancy Research Network FL cohort and Aristotle study FL cohort were used to assess the external validity.
Results
Among 44,127 FL cases from the Surveillance, Epidemiology, and End Results database, 1311 cases were pathology‐proven recorded to transform to diffuse large B‐cell lymphoma. The cumulative rates of HT at 5, 10, and 15 years after FL diagnosis were estimated to be 1.19%, 2.93%, and 5.01%, respectively. Significantly worse overall survival and cancer‐specific survival were exhibited in patients with HT than those without HT. Early HT (transformation of FL within 48 months after FL diagnosis [TOD48]) was an independent predictor for adverse overall survival of HT patients, regardless of treatment modalities before transformation. The adverse prognostic effect of TOD48 was validated in the Hematological Malignancy Research Network cohort and Aristotle study cohort. Older age (>75 years) and B symptoms within FL at diagnosis were the independent risk factors of TOD48. Furthermore, a novel prognostic model combining TOD48 with Follicular Lymphoma International Prognostic Index (TOD48‐FLIPI) was constructed and validated for risk stratification.
Conclusion
TOD48 was a risk indicator of HT, and the novel prognostic model "TOD48‐FLIPI" for HT patients was proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy.
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
- Hospital Universitario Central de Asturias - Insituto de investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Asturias, Spain.
ORCID-Profile: Hong-Hui Huang
Zitieren
APA
Li, Z. H., Zhang, M. Y., Federico, M., Civallero, M., Manni, M., Alonso-Alvarez, S., Hou, J., & Huang, H. H. (2024). Early histological transformation of follicular lymphoma to diffuse large B‐cell lymphoma indicating adverse survival: A population‐based analysis and validation. Cancer, 130(19), 3321-3332. https://doi.org/10.1002/cncr.35378
Vancouver
Li ZH, Zhang MY, Federico M, Civallero M, Manni M, Alonso-Alvarez S, et al. Early histological transformation of follicular lymphoma to diffuse large B‐cell lymphoma indicating adverse survival: A population‐based analysis and validation. Cancer. 2024;130(19):3321-3332. doi:10.1002/cncr.35378
BibTeX
@article{Li2024,
author = {Li, Zi-Hua and Zhang, Min-Yue and Federico, Massimo and Civallero, Monica and Manni, Martina and Alonso-Alvarez, Sara and Hou, Jian and Huang, Hong-Hui},
title = {Early histological transformation of follicular lymphoma to diffuse large B‐cell lymphoma indicating adverse survival: A population‐based analysis and validation},
journal = {Cancer},
year = {2024},
volume = {130},
number = {19},
pages = {3321--3332},
doi = {10.1002/cncr.35378}
}
EUVIMED